Bradley Foster & Sargent Inc. CT Has $24.37 Million Stock Position in Merck & Co., Inc. $MRK

Bradley Foster & Sargent Inc. CT reduced its position in shares of Merck & Co., Inc. (NYSE:MRK) by 4.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 290,335 shares of the company’s stock after selling 13,645 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in Merck & Co., Inc. were worth $24,368,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. DLD Asset Management LP acquired a new stake in shares of Merck & Co., Inc. in the second quarter valued at about $2,889,340,000. Norges Bank acquired a new position in shares of Merck & Co., Inc. during the 2nd quarter worth about $2,858,570,000. Franklin Resources Inc. boosted its stake in Merck & Co., Inc. by 23.5% during the 2nd quarter. Franklin Resources Inc. now owns 27,032,601 shares of the company’s stock valued at $2,139,901,000 after purchasing an additional 5,135,748 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in Merck & Co., Inc. by 35.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 19,456,096 shares of the company’s stock valued at $1,540,145,000 after purchasing an additional 5,094,088 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in Merck & Co., Inc. by 9.4% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 53,865,466 shares of the company’s stock valued at $4,263,991,000 after buying an additional 4,636,183 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Positive Phase 3 SMART trial results for ENFLONSIA (clesrovimab) in infants/children under 2 — expands the potential market for Merck’s RSV product and strengthens near-term growth prospects. Merck (MRK) Announces Positive Phase 3 SMART Trial Results for ENFLONSIA (Clesrovimab)
• Positive Sentiment: New Keytruda approvals/formulations (including subcutaneous option and additional indications) broaden dosing options and indications, supporting replacement revenue as competition increases. Merck RSV And KEYTRUDA Updates Refocus Attention On Valuation And Growth
• Positive Sentiment: Merck hit an annual high inside the Russell 1000 — technical/market-strength signal that complements fundamental newsflow. Merck (NYSE:MRK) Hits Annual High in Russell 1000
• Neutral Sentiment: Merck will present at the TD Cowen 46th Annual Health Care Conference — standard investor outreach that may provide management clarity but is not an immediate earnings driver. Merck to Participate in the TD Cowen 46th Annual Health Care Conference
• Neutral Sentiment: Analyst coverage and peer-comparison pieces show Merck is a relative outperformer but Wall Street remains cautiously optimistic — supports valuation but suggests limited near-term multiple expansion without more upside news. How Is Merck & Co.’s Stock Performance Compared to Other Healthcare Stocks?
• Negative Sentiment: Keytruda patent expiry (approaching 2028) is pushing Merck to split its human-health business and create a standalone cancer unit — a defensive move that signals meaningful future revenue pressure from biosimilars/generic competition. Market reaction has been muted, but the patent cliff remains the primary long-term risk to MRK’s top-line. Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports

Merck & Co., Inc. Trading Up 0.2%

Shares of Merck & Co., Inc. stock opened at $124.11 on Wednesday. The firm has a market capitalization of $308.03 billion, a PE ratio of 17.05, a price-to-earnings-growth ratio of 2.40 and a beta of 0.28. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.66 and a quick ratio of 1.44. The company’s fifty day moving average price is $111.65 and its two-hundred day moving average price is $96.63. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $124.84.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 45.22%. The company had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. During the same period last year, the firm earned $1.72 EPS. The firm’s revenue for the quarter was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Monday, March 16th. Merck & Co., Inc.’s payout ratio is presently 46.70%.

Insider Activity at Merck & Co., Inc.

In other news, CMO Chirfi Guindo sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $118.41, for a total value of $1,184,100.00. Following the sale, the chief marketing officer directly owned 70,615 shares in the company, valued at approximately $8,361,522.15. This represents a 12.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP David Michael Williams sold 5,000 shares of the stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $121.91, for a total value of $609,550.00. Following the completion of the transaction, the executive vice president directly owned 30,838 shares of the company’s stock, valued at approximately $3,759,460.58. The trade was a 13.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 320,176 shares of company stock valued at $38,281,735. Corporate insiders own 0.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on MRK. BMO Capital Markets upgraded Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $82.00 to $130.00 in a report on Thursday, December 18th. Citigroup boosted their target price on shares of Merck & Co., Inc. from $115.00 to $120.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Bank of America upped their target price on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, December 15th. UBS Group increased their price target on shares of Merck & Co., Inc. from $105.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Finally, Cantor Fitzgerald boosted their price objective on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $124.80.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.